Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Journey Medical Corporation DERM
$1.50
-$0.12 (-7.72%)
На 18:04, 12 мая 2023
Ранг: 2
Ключевые показатели
-
Marketcap
30140136.00000000
-
week52high
4.50
-
week52low
1.05
-
Revenue
73669000
-
P/E TTM
-1
-
Beta
0.00000000
-
EPS
-1.50000000
-
Last Dividend
0.00000000
-
Next Earnings Date
29 мар 2023 г. в 20:30
Описание компании
Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant acne; Targadox, an oral doxycycline drug for adjunctive therapy for severe acne; Ximino, an oral minocycline drug for the treatment of moderate to severe acne; and Exelderm cream and solution for topical use. It also sells doxycycline hyclate tablets, minocycline hydrocholoride capsules, and sulconazole nitrate cream and solution. The company was formerly known as Coronado Dermatology, Inc. and changed its name to Journey Medical Corporation. Journey Medical Corporation was incorporated in 2014 and is headquartered in Scottsdale, Arizona.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Cantor Fitzgerald | Overweight | 25 февр 2022 г. | |
| Roth Capital | Buy | 16 дек 2021 г. | |
| B. Riley Securities | Buy | 07 дек 2021 г. | |
| Mizuho | Buy | Neutral | 06 июн 2019 г. |
| H.C. Wainwright | Buy | Buy | 14 февр 2019 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| De Paolantonio Ernest Robert | A | 259907 | 10093 | 04 окт 2022 г. |
| ROSENWALD LINDSAY A MD | A | 14245 | 14245 | 21 июл 2022 г. |
| Smith Justin Adam | A | 44245 | 14245 | 21 июл 2022 г. |
| Herskowitz Neil | A | 44245 | 14245 | 21 июл 2022 г. |
| Paley Jeffrey | A | 44245 | 14245 | 21 июл 2022 г. |
| Toledano Miranda Jayne | A | 44245 | 14245 | 21 июл 2022 г. |
| De Paolantonio Ernest Robert | A | 270000 | 150000 | 21 июл 2022 г. |
| Maraoui Claude | A | 2192530 | 300000 | 21 июл 2022 г. |
| De Paolantonio Ernest Robert | A | 120000 | 120000 | 14 янв 2022 г. |
| Herskowitz Neil | A | 30000 | 30000 | 14 янв 2022 г. |
Новостная лента
Journey Medical Corporation (DERM) Q3 2022 Earnings Call Transcript
Seeking Alpha
12 ноя 2022 г. в 09:50
Journey Medical Corporation (NASDAQ:DERM ) Q3 2022 Earnings Conference Call November 10, 2022 4:30 PM ET Company Participants Matt Blazei – CORE IR Claude Maraoui – Co-Founder, President and Chief Executive Officer Ernie De Paolantonio – Chief Financial Officer Ramsey Alloush – General Counsel Conference Call Participants Scott Henry – ROTH Capital Brandon Folkes – Cantor Fitzgerald Operator Ladies and gentlemen, thank you for standing by. Good afternoon, and welcome to the Journey Medical's Third Quarter 2022 Financial Results and Corporate Update Conference Call.
Journey Medical Corporation (DERM) Reports Q3 Loss, Misses Revenue Estimates
Zacks Investment Research
10 ноя 2022 г. в 18:48
Journey Medical Corporation (DERM) delivered earnings and revenue surprises of -67.65% and 11.59%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Journey Medical Corporation to Announce Third Quarter 2022 Financial Results on November 10, 2022
GlobeNewsWire
03 ноя 2022 г. в 08:52
Company to host conference call to discuss financial results and provide a corporate update on November 10, 2022 at 4:30 p.m. ET Company to host conference call to discuss financial results and provide a corporate update on November 10, 2022 at 4:30 p.m. ET
Journey Medical Corporation to Participate in Upcoming October 2022 Investor Conferences
GlobeNewsWire
04 окт 2022 г. в 08:30
SCOTTSDALE, Ariz., Oct. 04, 2022 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical”) (Nasdaq: DERM), a commercial-stage pharmaceutical company that focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions, today announced that Claude Maraoui, President and Chief Executive Officer, will participate in two upcoming investor conferences.
Journey Medical Corporation (DERM) CEO Claude Maraoui on Q2 2022 Results - Earnings Call Transcript
Seeking Alpha
10 авг 2022 г. в 08:06
Journey Medical Corporation (NASDAQ:DERM ) Q2 2022 Results Conference Call August 9, 2022 4:30 PM ET Company Participants Claude Maraoui - Co-Founder President and Chief Executive Officer Ernest De Paolantonio - Chief Financial Officer Ramsey Alloush - General Counsel Dr. Srinivas Sidgiddi - Vice President of Clinical Development and Medical Affairs Jules Abraham - IR, CORE IR Conference Call Participants Brandon Folkes - Cantor Fitzgerald Mayank Mamtani - B. Riley FBR Operator Ladies and gentlemen, thank you for standing by.